{"id":47640,"date":"2013-03-15T18:30:32","date_gmt":"2013-03-15T17:30:32","guid":{"rendered":"http:\/\/www.bellunopress.it\/?p=47640"},"modified":"2013-03-15T18:30:32","modified_gmt":"2013-03-15T17:30:32","slug":"farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi","status":"publish","type":"post","link":"https:\/\/www.bellunopress.it\/fr\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/","title":{"rendered":"Farmaci in Veneto. Bond: &#8220;Perch\u00e9 limitare l&#8217;uso del Denosumab, ritenuto efficace sicuro e poco costoso per l&#8217;osteoporosi?&#8221;"},"content":{"rendered":"<figure id=\"attachment_42521\" aria-describedby=\"caption-attachment-42521\" style=\"width: 123px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/www.bellunopress.it\/wp-content\/uploads\/2012\/09\/bond.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-42521\" alt=\"Dario Bond\" src=\"http:\/\/www.bellunopress.it\/wp-content\/uploads\/2012\/09\/bond.jpg\" width=\"123\" height=\"150\" \/><\/a><figcaption id=\"caption-attachment-42521\" class=\"wp-caption-text\">Dario Bond<\/figcaption><\/figure>\n<p>\u201cIl sistema sanitario regionale non pu\u00f2 limitare la somministrazione di farmaci ritenuti sicuri ed efficaci dalla letteratura scientifica e dalla pratica. E\u2019 il caso del denosumab utilizzato per curare l\u2019osteoporosi\u201d.<\/p>\n<p>A dirlo \u00e8 il capogruppo del Pdl in Consiglio regionale Dario Bond che ha depositato un\u2019interrogazione rivolta all\u2019assessore alla sanit\u00e0 Luca Coletto sulla commercializzazione in Veneto del denosumab, conosciuto anche come Prolia, un anticorpo monoclonale completamente umano indicato per il trattamento dell\u2019osteoporosi post-menopausale, in particolare nelle forme pi\u00f9 gravi.<\/p>\n<p>\u201cNell\u2019agosto del 2011 l\u2019agenzia italiana del Farmaco ha stabilito che il denosumab \u00e8 soggetto a prescrizione medica da rinnovare volta per volta da parte dei centri ospedalieri dedicati e da parte degli specialisti quali l\u2019internista, l\u2019ortopedico, il reumatologo, il fisiatra, il geriatra e l\u2019endocrinologo\u201d, afferma Bond.<\/p>\n<p>\u201cNel dare attuazione alle indicazioni Aifa, la Regione Veneto, attraverso la Commissione competente, ha stabilito qualche mese dopo che il faramaco poteva essere prescritto solo dai centri gi\u00e0 autorizzati dalla Regione per la prescrizione dei farmaci teriparatide e ormone paratiroideo. In questo modo sono stati esclusi gli specialisti previsti invece dall\u2019Aifa\u201d.<\/p>\n<p>\u201cIn termini pratici questa limitazione comporta numerosi disagi per medici e pazienti, raddoppiando di fatto iter e costi. Di fronte infatti a una malattia trattabile con il denosumab lo specialista \u00e8 obbligato a ricorrere ai Centri previsti dalla Regione. Questo significa una doppia visita, una doppia consulenza specialistica e una doppia prescrizione\u201d.<\/p>\n<p>\u201cMi chiedo dove stia la logica ma soprattutto il risparmio\u201d, afferma Bond, \u201canche perch\u00e8 tale farmaco ha un costo inferiore, anche di dieci volte, rispetto al medicinale di riferimento per il trattamento dell\u2019osteoporosi complicata severa\u201d.<\/p>\n<p>Da qui la richiesta del capogruppo del Pdl all\u2019assessore competente: \u201cForse \u00e8 il caso di allineare la pratica regionale a quella nazionale. Il richio \u00e8 quello di creare una disparit\u00e0 di trattamento tra i malati di osteoporosi\u201d.<\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>\u201cIl sistema sanitario regionale non pu\u00f2 limitare la somministrazione di farmaci ritenuti sicuri ed efficaci dalla letteratura scientifica e dalla pratica. E\u2019 il caso del denosumab utilizzato per curare l\u2019osteoporosi\u201d. A dirlo \u00e8 il capogruppo del Pdl in Consiglio regionale Dario Bond che ha depositato un\u2019interrogazione rivolta all\u2019assessore alla sanit\u00e0 Luca Coletto sulla commercializzazione in [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,17],"tags":[],"class_list":["post-47640","post","type-post","status-publish","format-standard","category-prima-pagina","category-sanita"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Farmaci in Veneto. Bond: &quot;Perch\u00e9 limitare l&#039;uso del Denosumab, ritenuto efficace sicuro e poco costoso per l&#039;osteoporosi?&quot; - Bellunopress - Dolomiti<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bellunopress.it\/fr\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Farmaci in Veneto. Bond: &quot;Perch\u00e9 limitare l&#039;uso del Denosumab, ritenuto efficace sicuro e poco costoso per l&#039;osteoporosi?&quot; - Bellunopress - Dolomiti\" \/>\n<meta property=\"og:description\" content=\"\u201cIl sistema sanitario regionale non pu\u00f2 limitare la somministrazione di farmaci ritenuti sicuri ed efficaci dalla letteratura scientifica e dalla pratica. E\u2019 il caso del denosumab utilizzato per curare l\u2019osteoporosi\u201d. A dirlo \u00e8 il capogruppo del Pdl in Consiglio regionale Dario Bond che ha depositato un\u2019interrogazione rivolta all\u2019assessore alla sanit\u00e0 Luca Coletto sulla commercializzazione in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bellunopress.it\/fr\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/\" \/>\n<meta property=\"og:site_name\" content=\"Bellunopress - Dolomiti\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=100008943462799\" \/>\n<meta property=\"article:published_time\" content=\"2013-03-15T17:30:32+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.bellunopress.it\/wp-content\/uploads\/2012\/09\/bond.jpg\" \/>\n<meta name=\"author\" content=\"redazione\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@bellunopress\" \/>\n<meta name=\"twitter:site\" content=\"@bellunopress\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"redazione\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/\"},\"author\":{\"name\":\"redazione\",\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/#\\\/schema\\\/person\\\/79bb06722b37ece1c03d3e94beb30d73\"},\"headline\":\"Farmaci in Veneto. Bond: &#8220;Perch\u00e9 limitare l&#8217;uso del Denosumab, ritenuto efficace sicuro e poco costoso per l&#8217;osteoporosi?&#8221;\",\"datePublished\":\"2013-03-15T17:30:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/\"},\"wordCount\":335,\"publisher\":{\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.bellunopress.it\\\/wp-content\\\/uploads\\\/2012\\\/09\\\/bond.jpg\",\"articleSection\":[\"Prima Pagina\",\"Sanit\u00e0 Medicina\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/\",\"url\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/\",\"name\":\"Farmaci in Veneto. Bond: \\\"Perch\u00e9 limitare l'uso del Denosumab, ritenuto efficace sicuro e poco costoso per l'osteoporosi?\\\" - Bellunopress - Dolomiti\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.bellunopress.it\\\/wp-content\\\/uploads\\\/2012\\\/09\\\/bond.jpg\",\"datePublished\":\"2013-03-15T17:30:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.bellunopress.it\\\/wp-content\\\/uploads\\\/2012\\\/09\\\/bond.jpg\",\"contentUrl\":\"http:\\\/\\\/www.bellunopress.it\\\/wp-content\\\/uploads\\\/2012\\\/09\\\/bond.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/2013\\\/03\\\/15\\\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.bellunopress.it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Farmaci in Veneto. Bond: &#8220;Perch\u00e9 limitare l&#8217;uso del Denosumab, ritenuto efficace sicuro e poco costoso per l&#8217;osteoporosi?&#8221;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/#website\",\"url\":\"https:\\\/\\\/www.bellunopress.it\\\/\",\"name\":\"Bellunopress - Dolomiti\",\"description\":\"e-mail: redazione@bellunopress.it\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.bellunopress.it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/#organization\",\"name\":\"Bellunopress\",\"url\":\"https:\\\/\\\/www.bellunopress.it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.bellunopress.it\\\/wp-content\\\/uploads\\\/2011\\\/05\\\/cropped-logo-bellunopress-.jpg\",\"contentUrl\":\"https:\\\/\\\/www.bellunopress.it\\\/wp-content\\\/uploads\\\/2011\\\/05\\\/cropped-logo-bellunopress-.jpg\",\"width\":512,\"height\":512,\"caption\":\"Bellunopress\"},\"image\":{\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=100008943462799\",\"https:\\\/\\\/x.com\\\/bellunopress\",\"https:\\\/\\\/www.linkedin.com\\\/hp\\\/?dnr=JBzUWaJfMUw8vbXJJ2tVW5-I3jZKvC4wsoxE&amp;amp;amp;amp;amp;amp;trk=nav_responsive_tab_home\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCxL0wu1uN0_3_7hGG0306cw\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.bellunopress.it\\\/#\\\/schema\\\/person\\\/79bb06722b37ece1c03d3e94beb30d73\",\"name\":\"redazione\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/37d968a2e67a6fd04c169c4bdef102d0bc5d31b2546345219e348575eb80e9a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/37d968a2e67a6fd04c169c4bdef102d0bc5d31b2546345219e348575eb80e9a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/37d968a2e67a6fd04c169c4bdef102d0bc5d31b2546345219e348575eb80e9a0?s=96&d=mm&r=g\",\"caption\":\"redazione\"},\"sameAs\":[\"http:\\\/\\\/www.bellunopress.it\",\"https:\\\/\\\/x.com\\\/bellunopress\"],\"url\":\"https:\\\/\\\/www.bellunopress.it\\\/fr\\\/author\\\/redazione\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Farmaci in Veneto. Bond: \"Perch\u00e9 limitare l'uso del Denosumab, ritenuto efficace sicuro e poco costoso per l'osteoporosi?\" - Bellunopress - Dolomiti","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bellunopress.it\/fr\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/","og_locale":"fr_FR","og_type":"article","og_title":"Farmaci in Veneto. Bond: \"Perch\u00e9 limitare l'uso del Denosumab, ritenuto efficace sicuro e poco costoso per l'osteoporosi?\" - Bellunopress - Dolomiti","og_description":"\u201cIl sistema sanitario regionale non pu\u00f2 limitare la somministrazione di farmaci ritenuti sicuri ed efficaci dalla letteratura scientifica e dalla pratica. E\u2019 il caso del denosumab utilizzato per curare l\u2019osteoporosi\u201d. A dirlo \u00e8 il capogruppo del Pdl in Consiglio regionale Dario Bond che ha depositato un\u2019interrogazione rivolta all\u2019assessore alla sanit\u00e0 Luca Coletto sulla commercializzazione in [&hellip;]","og_url":"https:\/\/www.bellunopress.it\/fr\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/","og_site_name":"Bellunopress - Dolomiti","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=100008943462799","article_published_time":"2013-03-15T17:30:32+00:00","og_image":[{"url":"http:\/\/www.bellunopress.it\/wp-content\/uploads\/2012\/09\/bond.jpg","type":"","width":"","height":""}],"author":"redazione","twitter_card":"summary_large_image","twitter_creator":"@bellunopress","twitter_site":"@bellunopress","twitter_misc":{"Written by":"redazione","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/#article","isPartOf":{"@id":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/"},"author":{"name":"redazione","@id":"https:\/\/www.bellunopress.it\/#\/schema\/person\/79bb06722b37ece1c03d3e94beb30d73"},"headline":"Farmaci in Veneto. Bond: &#8220;Perch\u00e9 limitare l&#8217;uso del Denosumab, ritenuto efficace sicuro e poco costoso per l&#8217;osteoporosi?&#8221;","datePublished":"2013-03-15T17:30:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/"},"wordCount":335,"publisher":{"@id":"https:\/\/www.bellunopress.it\/#organization"},"image":{"@id":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/#primaryimage"},"thumbnailUrl":"http:\/\/www.bellunopress.it\/wp-content\/uploads\/2012\/09\/bond.jpg","articleSection":["Prima Pagina","Sanit\u00e0 Medicina"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/","url":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/","name":"Farmaci in Veneto. Bond: \"Perch\u00e9 limitare l'uso del Denosumab, ritenuto efficace sicuro e poco costoso per l'osteoporosi?\" - Bellunopress - Dolomiti","isPartOf":{"@id":"https:\/\/www.bellunopress.it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/#primaryimage"},"image":{"@id":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/#primaryimage"},"thumbnailUrl":"http:\/\/www.bellunopress.it\/wp-content\/uploads\/2012\/09\/bond.jpg","datePublished":"2013-03-15T17:30:32+00:00","breadcrumb":{"@id":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/#primaryimage","url":"http:\/\/www.bellunopress.it\/wp-content\/uploads\/2012\/09\/bond.jpg","contentUrl":"http:\/\/www.bellunopress.it\/wp-content\/uploads\/2012\/09\/bond.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.bellunopress.it\/2013\/03\/15\/farmaci-in-veneto-bond-perche-limitare-luso-del-denosumab-ritenuto-efficace-sicuro-e-poco-costoso-per-losteoporosi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bellunopress.it\/"},{"@type":"ListItem","position":2,"name":"Farmaci in Veneto. Bond: &#8220;Perch\u00e9 limitare l&#8217;uso del Denosumab, ritenuto efficace sicuro e poco costoso per l&#8217;osteoporosi?&#8221;"}]},{"@type":"WebSite","@id":"https:\/\/www.bellunopress.it\/#website","url":"https:\/\/www.bellunopress.it\/","name":"Bellunopress - Dolomiti","description":"e-mail: redazione@bellunopress.it","publisher":{"@id":"https:\/\/www.bellunopress.it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bellunopress.it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.bellunopress.it\/#organization","name":"Bellunopress","url":"https:\/\/www.bellunopress.it\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.bellunopress.it\/#\/schema\/logo\/image\/","url":"https:\/\/www.bellunopress.it\/wp-content\/uploads\/2011\/05\/cropped-logo-bellunopress-.jpg","contentUrl":"https:\/\/www.bellunopress.it\/wp-content\/uploads\/2011\/05\/cropped-logo-bellunopress-.jpg","width":512,"height":512,"caption":"Bellunopress"},"image":{"@id":"https:\/\/www.bellunopress.it\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=100008943462799","https:\/\/x.com\/bellunopress","https:\/\/www.linkedin.com\/hp\/?dnr=JBzUWaJfMUw8vbXJJ2tVW5-I3jZKvC4wsoxE&amp;amp;amp;amp;amp;amp;trk=nav_responsive_tab_home","https:\/\/www.youtube.com\/channel\/UCxL0wu1uN0_3_7hGG0306cw"]},{"@type":"Person","@id":"https:\/\/www.bellunopress.it\/#\/schema\/person\/79bb06722b37ece1c03d3e94beb30d73","name":"r\u00e9daction","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/37d968a2e67a6fd04c169c4bdef102d0bc5d31b2546345219e348575eb80e9a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/37d968a2e67a6fd04c169c4bdef102d0bc5d31b2546345219e348575eb80e9a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/37d968a2e67a6fd04c169c4bdef102d0bc5d31b2546345219e348575eb80e9a0?s=96&d=mm&r=g","caption":"redazione"},"sameAs":["http:\/\/www.bellunopress.it","https:\/\/x.com\/bellunopress"],"url":"https:\/\/www.bellunopress.it\/fr\/author\/redazione\/"}]}},"_links":{"self":[{"href":"https:\/\/www.bellunopress.it\/fr\/wp-json\/wp\/v2\/posts\/47640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bellunopress.it\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bellunopress.it\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bellunopress.it\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bellunopress.it\/fr\/wp-json\/wp\/v2\/comments?post=47640"}],"version-history":[{"count":1,"href":"https:\/\/www.bellunopress.it\/fr\/wp-json\/wp\/v2\/posts\/47640\/revisions"}],"predecessor-version":[{"id":47641,"href":"https:\/\/www.bellunopress.it\/fr\/wp-json\/wp\/v2\/posts\/47640\/revisions\/47641"}],"wp:attachment":[{"href":"https:\/\/www.bellunopress.it\/fr\/wp-json\/wp\/v2\/media?parent=47640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bellunopress.it\/fr\/wp-json\/wp\/v2\/categories?post=47640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bellunopress.it\/fr\/wp-json\/wp\/v2\/tags?post=47640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}